Osteoporosis News and Research

Latest Osteoporosis News and Research

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

Research offers further evidence that diet affects gastrointestinal illnesses

Research being presented at Digestive Disease Week- offers further evidence that diet affects gastrointestinal illnesses, such as gallstones and celiac disease, and that some patients who think their digestive problems are caused by lactose intolerance are actually reacting to a psychological disorder.

9 May 2011

Study analyzes breast-feeding frequency of infants in eight inner-city Philadelphia health centers

"Breastfeeding is a hot topic. We know it is beneficial for most babies and that many are not getting breastfed," said lead study author Jessica Robbins, Ph.D., a public health epidemiologist with the Philadelphia Department of Public Health.

7 May 2011

$Bone building drugs bisphosphonates lead to only a marginally higher risk of fractures: Study$

Bone building drugs bisphosphonates lead to only a marginally higher risk of fractures: Study

According to a new study, nearly 78% of all Swedish women aged 55 years and older who sustained a thigh bone or femur fracture in 2008 had taken bisphosphonates for their osteoporosis. However the authors of the study published in the May 5 issue of the New England Journal of Medicine (NEJM) write that the absolute risk for such breaks is small enough to justify prescribing the drugs.

5 May 2011

$Study: Bisphosphonates can cause fatigue fractures$

Study: Bisphosphonates can cause fatigue fractures

Bisphosphonates are a medication that has been administered since the 1990s, which reduces the overall risk of brittleness and incidence of osteoporosis. Bisphosphonates deactivate those cells used to break down bone and therefore prevent fractures caused by brittleness of the bone.

5 May 2011

Regular dose of sunshine could help prevent falls

Regular exposure to sunshine to maintain adequate vitamin D levels could help prevent falls in the elderly.

3 May 2011

Calcium and vitamin D intake before bone density test can reduce risk of osteoporosis

Has a bone density scan placed you at risk for osteoporosis, leading your doctor to prescribe a widely advertised bone-building medication? Not so fast! A University of Illinois study finds that an effective first course of action is increasing dietary calcium and vitamin D or taking calcium and vitamin D supplements.

3 May 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

$Hyponatremia linked to high risk of fractures in elderly patients$

Hyponatremia linked to high risk of fractures in elderly patients

A common blood disorder, hyponatremia, may be a risk factor for fractures in elderly patients, new research presented at the European Congress of Endocrinology shows.

3 May 2011

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain.

30 Apr 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011

IOF, ANZBMS to hold osteoporosis and bone meeting in Asia-Pacific region

IOF and the ANZBMS, together with the Japanese Bone and Mineral Research Society, invite researchers and clinicians with an interest in osteoporosis and bone research to attend the year's most important bone meeting in the Asia-Pacific region.

29 Apr 2011

Study focuses on calcium intake among U.S. population

Americans may not be getting enough calcium in their diets, according to a new study published in the May 2011 issue of the Journal of the American Dietetic Association.

28 Apr 2011

Softgels as effective as tablets in delivering folic acid

Folic acid, an essential vitamin formulated to be part of a multivitamin + DHA liquid softgel capsule, is absorbed and available within the body in amounts similar to folic acid formulated for solid tablets, according to a study presented in a late breaking session at the Experimental Biology (EB) 2011 annual meeting.

28 Apr 2011

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

28 Apr 2011

Study identifies major osteoporosis knowledge gaps for some patient groups

A fracture in a person over the age of 50 can be a sign of osteoporosis, yet some patient populations have little knowledge of the disease. According to a groundbreaking study published in a recent Journal of Bone and Joint Surgery (JBJS), male and non-English speaking patients tend to have the least knowledge of osteoporosis, putting them at high risk for a subsequent fracture.

22 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

Parents open to genetic tests for children

Genetic testing techniques have not been perfected yet but parents are willing to take the risk to know if their children are at risk for diseases in adulthood. Some parents would like the ability to predict the future, in terms of their child's risk for certain chronic health conditions. This comes in a new study published online in the journal Pediatrics. Experts, however, say the tests are of little value at this time.

19 Apr 2011